Advertisement

Topics

Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting

09:50 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
In a phase Ib/II investigational study of duvelisib, a dual inhibitor of PI3K-δ,γ in combination with FCR (dFCR) for frontline therapy of younger CLL patients, dFCR was observed to be a highly active regimen, achieving ORR of ...

Other Sources for this Article

Verastem Oncology, Inc.
Marianne M. Lambertson
Vice President, Corporate Communications
Investor Relations/Public Relations
+1 781-292-4273
mlambertson@verastem.com

NEXT ARTICLE

More From BioPortfolio on "Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...